Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients
Metadatos
Mostrar el registro completo del ítemAutor
Riquelme Gallego, Blanca; Sánchez-Delgado, Guillermo; González Salvatierra, Sheila; García Recio, Enrique; Muñoz Torres, Manuel EduardoEditorial
Nature Research
Fecha
2020-02-04Referencia bibliográfica
Riquelme-Gallego, B., García-Molina, L., Cano-Ibáñez, N., Sánchez-Delgado, G., Andújar-Vera, F., García-Fontana, C., ... & Muñoz-Torres, M. (2020). Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Scientific reports, 10(1), 1-10. [https://doi.org/10.1038/s41598-020-58760-7]
Patrocinador
Junta de Andalucia PI-0207-2016; European Union (EU) PI18-00803 PI18-01235Resumen
Undercarboxylated osteocalcin (ucOC) could be a biomarker of glucose disturbances and cardiovascular
risk. Our study aimed to determine the association between serum levels of ucOC and cardiovascular
risk in metabolic syndrome (MetS) patients and to analyse its potential role as estimator of type 2
diabetes (T2D) risk in this population. This cross-sectional study included 235 patients with MetS,
53.2% women, aged 55–75 years. Circulating ucOC levels were measured by ELISA. Cardiovascular risk
was determined as Z-score of the diagnostic criteria for MetS (CV-ZS). Linear regression model was
performed to analyse the association between circulating ucOC and CV-ZS. A receiver operating curve
(ROC) was performed to analyse the usefulness of ucOC as T2D risk estimator. Patients above the CV-ZS
median showed signifcant lower ucOC levels. We found an inverse association between ucOC levels and
CV-ZS in MetS patients without T2D. Patients with ucOC levels below the 25th percentile showed worse
cardiometabolic profle and higher cardiovascular and T2D risk. The area under the curve performed
better when ucOC levels were included along with the classic T2D risk factors. The measurement of
circulating ucOC could be a useful tool to identify increased cardiovascular and T2D risk in MetS patients
without T2D.